While the development of immunotherapeutic approaches targeting endogenous tumor antigens remains the primary goal in glioma models, the low frequencies of CD8+ T cells responding to these antigens presents a significant challenge to the study of T cell immunity. Here, CD8A is linked to central nervous system cancer.